Featured Research

from universities, journals, and other organizations

Comparison of medications for heart failure finds difference in risk of death

Date:
January 13, 2011
Source:
JAMA and Archives Journals
Summary:
In a comparison of the angiotensin II receptor blockers candesartan and losartan, used by patients with heart failure, candesartan was associated with a lower risk of death at 1 and 5 years, according to a new study.

In a comparison of the angiotensin II receptor blockers (ARBs) candesartan and losartan, used by patients with heart failure, candesartan was associated with a lower risk of death at 1 and 5 years, according to a study in the January 12 issue of JAMA.

Related Articles


Angiotensin II receptor blockers reduce cardiovascular mortality and heart failure (HF) hospitalization in patients with HF with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction). Despite variable effects of different ARBs, they have not been tested head to head, and there are reasons to believe they may differ in efficacy, according to background information in the article. Previous research found that in elderly patients with HF, losartan was associated with higher mortality than other ARBs.

Maria Eklind-Cervenka, M.D., of the Department of Cardiology, South Hospital, Stockholm, and colleagues conducted a study to determine whether candesartan is associated with less all-cause mortality than losartan in patients with HF. The study included analysis of data from an HF registry (the Swedish Heart Failure Registry) of 30,254 patients registered from 62 hospitals and 60 outpatient clinics between 2000 and 2009. A total of 5,139 patients (average age, 74; 39 percent women) were treated with candesartan (n = 2,639) or losartan (n = 2,500).

In overall survival between the 2 groups, the researchers found that one-year survival was 90 percent for patients receiving candesartan and 83 percent for patients receiving losartan, and 5-year survival was 61 percent for patients receiving candesartan and 44 percent for patients receiving losartan. The results persisted in stratified analyses.

The researchers add that there are mechanistic reasons to believe candesartan may be more effective than losartan and that studies of candesartan have been larger and more conclusively positive than studies of losartan.

"In conclusion, our findings suggest that candesartan is associated with less all-cause mortality than losartan. However, clinical decision making should await supportive evidence of this observed association. Ideally, different ARB agents should be tested against each other in randomized controlled trials. It would also be important and perhaps more feasible to confirm our findings in other large HF registries," the authors write.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Eklind-Cervenka, L. Benson, U. Dahlstrom, M. Edner, M. Rosenqvist, L. H. Lund. Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure. JAMA: The Journal of the American Medical Association, 2011; 305 (2): 175 DOI: 10.1001/jama.2010.1949

Cite This Page:

JAMA and Archives Journals. "Comparison of medications for heart failure finds difference in risk of death." ScienceDaily. ScienceDaily, 13 January 2011. <www.sciencedaily.com/releases/2011/01/110111165009.htm>.
JAMA and Archives Journals. (2011, January 13). Comparison of medications for heart failure finds difference in risk of death. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2011/01/110111165009.htm
JAMA and Archives Journals. "Comparison of medications for heart failure finds difference in risk of death." ScienceDaily. www.sciencedaily.com/releases/2011/01/110111165009.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com
Flu Outbreak Closing Schools in Ohio

Flu Outbreak Closing Schools in Ohio

AP (Dec. 17, 2014) A wave of flu illnesses has forced some Ohio schools to shut down over the past week. State officials confirmed one pediatric flu-related death, a 15-year-old girl in southern Ohio. (Dec. 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins